Arcturus Therapeutics (ARCT) News Today $12.20 -0.60 (-4.69%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$12.26 +0.06 (+0.46%) As of 05/23/2025 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock ARCT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Arcturus Therapeutics (NASDAQ:ARCT) Upgraded at StockNews.comStockNews.com raised Arcturus Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday.May 24 at 10:55 AM | marketbeat.comWoodline Partners LP Has $13.69 Million Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Woodline Partners LP boosted its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 3.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 806,912 shares of the biotMay 24 at 5:02 AM | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Upgraded by Wall Street Zen to "Hold" RatingMay 24 at 1:25 AM | americanbankingnews.comWilliam Blair Has Positive Estimate for ARCT Q2 EarningsMay 17, 2025 | americanbankingnews.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Acquired by MPM Bioimpact LLCMPM Bioimpact LLC lifted its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 109.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 459,943 shares of the biotecMay 16, 2025 | marketbeat.comCantor Fitzgerald Has Positive View of ARCT FY2025 EarningsMay 16, 2025 | americanbankingnews.comLeerink Partnrs Analysts Raise Earnings Estimates for ARCTMay 16, 2025 | americanbankingnews.comCanaccord Genuity Group Lowers Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $66.00Canaccord Genuity Group dropped their price target on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating for the company in a research report on Tuesday.May 15, 2025 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Releases Quarterly Earnings ResultsArcturus Therapeutics (NASDAQ:ARCT - Get Free Report) released its quarterly earnings data on Monday. The biotechnology company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($1.10) by $0.58. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%.May 14, 2025 | marketbeat.com296,045 Shares in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Bought by J. Goldman & Co LPJ. Goldman & Co LP purchased a new position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 296,045 shares of the biotechnology company's stock, vMay 14, 2025 | marketbeat.comQ1 2025 Arcturus Therapeutics Holdings Inc Earnings CallMay 14, 2025 | uk.finance.yahoo.comArcturus signals extended cash runway into 2028 with strategic shift toward CF and OTC mRNA therapeuticsMay 12, 2025 | msn.comArcturus Therapeutics Holdings Inc. (ARCT) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comBalyasny Asset Management L.P. Acquires New Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Balyasny Asset Management L.P. bought a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 548,761 shares of the biotechnology company's stock, valued at aMay 12, 2025 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Dimensional Fund Advisors LPDimensional Fund Advisors LP cut its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 10.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 707,404 shares of the biotechnology company's sMay 12, 2025 | marketbeat.comEarnings To Watch: Arcturus Therapeutics Holdings Inc (ARCT) Reports Q1 2025 ResultMay 9, 2025 | finance.yahoo.comArcturus Therapeutics (ARCT) to Release Quarterly Earnings on MondayArcturus Therapeutics (NASDAQ:ARCT) will be releasing its Q1 2025 earnings after the market closes on Monday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-12-arcturus-therapeutics-holdings-inc-stock/)May 7, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Acquires 479,482 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Schonfeld Strategic Advisors LLC lifted its holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 129.7% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 849,081 shares of the biotechnology company's sMay 2, 2025 | marketbeat.comBoothbay Fund Management LLC Makes New $1 Million Investment in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Boothbay Fund Management LLC bought a new stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 58,944 shares of the biotechnology company'May 2, 2025 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of "Buy" from AnalystsArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has received an average recommendation of "Buy" from the eight ratings firms that are presently covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation and one has assigned a stronMay 1, 2025 | marketbeat.comSumitomo Mitsui Trust Group, Inc. Reduces Stake in Arcturus Therapeutics Holdings Inc.April 30, 2025 | gurufocus.comResearch Analysts Offer Predictions for ARCT Q1 EarningsArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Arcturus Therapeutics in a research report issued on Wednesday, April 16th. Leerink Partnrs analyst L. Nsongo anticipates that the biApril 20, 2025 | marketbeat.comArcturus Therapeutics (ARCT) Gets a Hold from Leerink PartnersApril 17, 2025 | markets.businessinsider.comVanguard Group Inc. Grows Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Vanguard Group Inc. boosted its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 6.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,684,561 shares of the bioteApril 16, 2025 | marketbeat.comArcturus Therapeutics granted fast track designation for ARCT-2304 from FDAApril 11, 2025 | markets.businessinsider.comHigh Growth Tech Stocks To Watch In The US April 2025April 11, 2025 | finance.yahoo.comArcturus Therapeutics price target lowered to $45 from $71 at GuggenheimApril 11, 2025 | markets.businessinsider.comArcturus Gets FDA Fast-Track Designation for Pandemic Influenza A H5N1 VaccineApril 10, 2025 | marketwatch.comArcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1April 10, 2025 | finance.yahoo.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of "Buy" by AnalystsArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has been assigned a consensus rating of "Buy" from the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation and one has assigneApril 6, 2025 | marketbeat.comBank of New York Mellon Corp Sells 22,024 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Bank of New York Mellon Corp trimmed its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 22.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 78,180 shares of the biotechnology company's stock after selliMarch 24, 2025 | marketbeat.comIs Arcturus Therapeutics (ARCT) a Worst High-Risk High-Reward Growth Stock to Buy?March 20, 2025 | insidermonkey.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Nikko Asset Management Americas Inc.Nikko Asset Management Americas Inc. reduced its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 10.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,065,050 shares of the biotechnoMarch 18, 2025 | marketbeat.com2 Growth Stocks to Buy Now With 367% to 410% UpsideMarch 17, 2025 | msn.comWilliam Blair Issues Pessimistic Outlook for ARCT EarningsArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) - Equities researchers at William Blair dropped their Q1 2025 earnings per share (EPS) estimates for Arcturus Therapeutics in a research report issued to clients and investors on Thursday, March 13th. William Blair analyst M. MinterMarch 17, 2025 | marketbeat.comJupiter Asset Management Ltd. Lowers Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Jupiter Asset Management Ltd. lessened its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 9.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 319,446 shares of tMarch 14, 2025 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Bank Julius Baer & Co. Ltd ZurichBank Julius Baer & Co. Ltd Zurich lowered its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 91.8% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,084 shares of the biotechnology company's stock after selling 23,20March 12, 2025 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Price Target Lowered to $68.00 at Canaccord Genuity GroupCanaccord Genuity Group decreased their price target on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a "buy" rating for the company in a report on Monday.March 10, 2025 | marketbeat.comArcturus Therapeutics price target lowered to $68 from $74 at CanaccordMarch 10, 2025 | markets.businessinsider.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) have earned a consensus rating of "Buy" from the eight research firms that are covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has assigned a stMarch 10, 2025 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Are Cutting Their Estimates: Here's What You Need To KnowMarch 9, 2025 | finance.yahoo.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2024 Earnings Call TranscriptMarch 8, 2025 | msn.comArcturus Therapeutics (NASDAQ:ARCT) Price Target Lowered to $60.00 at HC WainwrightHC Wainwright decreased their price target on shares of Arcturus Therapeutics from $63.00 to $60.00 and set a "buy" rating on the stock in a research note on Friday.March 8, 2025 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Receives Overweight Rating from Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating on shares of Arcturus Therapeutics in a research report on Friday.March 8, 2025 | marketbeat.comWells Fargo & Company Has Lowered Expectations for Arcturus Therapeutics (NASDAQ:ARCT) Stock PriceWells Fargo & Company decreased their price target on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an "overweight" rating for the company in a research note on Friday.March 8, 2025 | marketbeat.comQ4 2024 Arcturus Therapeutics Holdings Inc Earnings CallMarch 7, 2025 | finance.yahoo.comArcturus Therapeutics (ARCT) Gets a Buy from Wells FargoMarch 7, 2025 | markets.businessinsider.comBeyond The Numbers: 8 Analysts Discuss Arcturus Therapeutics StockMarch 7, 2025 | benzinga.comArcturus Therapeutics price target lowered to $60 from $63 at H.C. WainwrightMarch 7, 2025 | markets.businessinsider.comArcturus Therapeutics (NASDAQ:ARCT) Issues Earnings Results, Misses Expectations By $0.78 EPSArcturus Therapeutics (NASDAQ:ARCT - Get Free Report) issued its earnings results on Thursday. The biotechnology company reported ($1.11) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.78). Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%.March 7, 2025 | marketbeat.com Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Email Address ARCT Media Mentions By Week ARCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARCT News Sentiment▼0.950.75▲Average Medical News Sentiment ARCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARCT Articles This Week▼34▲ARCT Articles Average Week Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ocular Therapeutix News Calliditas Therapeutics AB (publ) News Qilian International Holding Group News Amphastar Pharmaceuticals News 89bio News Aurinia Pharmaceuticals News Gyre Therapeutics News Mineralys Therapeutics News Wave Life Sciences News Phibro Animal Health News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARCT) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
